ATG returns to Berlin Life Sciences Conference with new antimicrobial technologies
Press Release | ATG:biosynthetics GmbH
MARCH 01, 2018
Merzhausen, Germany: – German-based biotechnological company and research organization ATG:biosynthetics (ATG) is returning to the Berlin Conference on Life Sciences as it focuses on novel antimicrobial technologies.
ATG’s CEO. Dr. Hubert S. Bernauer, will again represent the company at the conference, now in its eleventh year.
Expertise in vaccine biodesign
This year’s Berlin conference, being held at the Fraunhofer-Forum Berlin (Spree Palais) will focus on ‘Novel anti-microbials and AMR Diagnostics’.
These are fields in which ATG:biosynthetics is a European leader with its expertise in bioinformatics, synthetic biology, gene and pathway design, library and expression vector design/synthesis. ATG’s novel epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology.
PepID algorithms – surfome mapping for “ONE look ALL B-cell epitopes,” identification
ATG’s strong PepID’s computational algorithms in genomic bioinformatics allow it to generate relevance. Selected deterministic PepIDIS in silico peptide libraries are realized on “high density peptide micro arrays” for screening purposes. For in vivo studies in life vaccines DNA-encoded PepIDEBP sub-libraries can then be expressed for antibody recognition, either by colony immunoblotting or using cell surface display and FACS. The new methodology aims on maximizing the efficacy of multi-epitope vaccines.
“I am looking forward to returning to this great event,” said Dr. Bernauer.
“The Berlin Life Sciences Conference gives us a great opportunity to meet some of the most eminent colleagues in the antimicrobial field,” he continued.
“It is also a rich source of industry-leading thought and perspectives, where we can gather new inspiration for our future avenues of research and business development in antimicrobial drug design,” Dr. Bernauer added.
About ATG: biosynthetics
Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.
ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.
ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.
About Berlin Conference on Life Sciences
Over its eleven-year history, the Berlin Conference on Life Sciences has become a highly respected annual event for Life Science decision makers, business developers, investors and legal experts.
The 11th Berlin Conference on Life Sciences is a one-day event on March 2, 2018, held at the Fraunhofer-Forum alongside the River Spree.
The 2018 event theme is the exciting market for the development of novel antimicrobials and AMR diagnostics.
Conference sessions include an industry overview, R&D trends and technology perspectives on new approaches to combating antimicrobial resistance, promising molecular methods of detecting multiple drug resistance and a legal perspective on the challenges of bringing antimicrobials to the market.
The event is organized by Biocom AG, with more information at: http://berlin-conferences.com/home/.
Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424